Medical School or Training
N.H.L Municipal Medical College, 1988
K.M. School Post Graduate Study and Research, Pediatrics, 1992
SUNY Health Science Center, Pediatrics, NY, 1997
Pediatric Oncology, Gujarat Cancer & Research Institute MP Shah Cancer Hospital, 1994
Pediatric Hematology/Oncology, University of Michigan Medical Center, 2000
American Society of Pediatric Hemtology-Oncology
American Association of Cancer Research
Children's Oncology Group
American Society of Hematology
Dr. Mody’s primary research interest is in development of new drugs against childhood cancers. He is the Principal Investigator of International Phase-II, randomized trial of Chimeric 14.18 or Temsirolimus in combination with Irinotecan/ Temozolomide by the Children’s Oncology Group (COG). He is also conducting a Phase-I trial of Bortezomib in combination with Irinotecan in refractory / relapsed neuroblastoma. He is a member of the High Risk Neurobalstoma Committee of COG and is the Principle Investigator of the Children's Oncology Group, Phase-I/ Phase II-III Consortium studies at C.S. Mott Children's Hospital.
Dr. Mody is also investigating role Precision Medicine in Pediatric Oncology through Next Generation Sequencing (NGS) in collaboration with the laboratory of Dr. Arul Chinnaiyan in the Michigan Center of Translational Pathology (MCTP).
Dr. Mody’s other interests include health related outcomes of childhood cancer survivors.
Dr. Rajen Mody joined the Division of Pediatric Hematology/Oncology following completion of his fellowship training in pediatric hematology/oncology at the University of Michigan. He subsequently completed his Masters in Science (MS) in clinical trials design and biostatistics at the school of public health at the university of Michigan. Before coming to Michigan, Dr. Mody completed a pediatric residency and chief residency at the State University of New York, in New York City. His research interests include new drug development against childhood cancers and role of precision medicine in pediatric oncology.